Aptose Biosciences Reports Promising Results for Novel AML Therapy in Clinical Trial
Aptose Biosciences Inc. has reported promising clinical trial results for its novel AML therapy, Tuspetinib Triplet Therapy, which achieved complete remissions and minimal residual disease negativity in 10 patients with varying AML mutations.
2 minutes to read